NCT06448910View on ClinicalTrials.gov

Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2027

Conditions
NSCLCLocally Advanced Lung Carcinoma
Interventions
DRUG

Cadonilimab (AK104)

Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06448910 - Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | Biotech Hunter | Biotech Hunter